142
3
28
1
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T9651 | PD-1/PD-L1-IN-9 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in... | |||
T9616 | PD-1/PD-L1-IN-10 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. | |||
T3655 | BMS-1 | PD1-PDL1 inhibitor 1,PD-1/PD-L1 inhibitor 1 | Apoptosis , PD-1/PD-L1 |
BMS-1 (PD-1/PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene ... | |||
T36900 | PD-1/PD-L1-IN-NP19 | PD-1/PD-L1-IN-NP19 | PD-1/PD-L1 |
PD-1/PD-L1-IN-NP19, a PD-1/PD-L1 inhibitor, exhibits an IC50 of 12.5 nM against the human PD-1/PD-L1 interaction, potentially activating the tumor immune microenvironment and contributing to its antitumor effects[1]. | |||
T40112 | PROTAC PD-1/PD-L1 degrader-1 | PROTAC PD-1/PD-L1 degrader-1 | |
PROTAC PD-1/PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1/PD-L1 PROTAC that effectively inhibits the interaction between PD-1 and PD-L1 with an IC50 value of 39.2 nM. It successfully restores the suppr... | |||
T36899 | INCB086550 | PD-1/PD-L1-IN-8 | PD-1/PD-L1 |
INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. | |||
T39591 | Human PD-L1 inhibitor I | Human PD-L1 inhibitor I | |
Human PD-L1 inhibitor I is a peptide ligand that specifically inhibits the interaction between human PD-L1 and human PD-1. It exhibits a KD value of 3.39 μM, indicating its binding affinity. The presence of Human PD-L1 i... | |||
T36487 | Evixapodlin | PD-1/PD-L1-IN 7,GS-4224 | Antiviral , HBV , PD-1/PD-L1 |
Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. | |||
T39589 | Human PD-L1 inhibitor III | Human PD-L1 inhibitor III | |
Human PD-L1 inhibitor III is a human PD-L1 inhibitor. | |||
T39590 | Human PD-L1 inhibitor II | Human PD-L1 inhibitor II | |
Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity. | |||
T39588 | Human PD-L1 inhibitor IV | Human PD-L1 inhibitor IV | |
Human PD-L1 inhibitor IV is a polypeptide compound that competitively inhibits the human PD-1 protein. It has a Kd value of 1.38 μM and effectively blocks the interaction between hPD-1 and hPD-L1. | |||
T12380 | PD-1/PD-L1-IN 5 TFA | PD-1/PD-L1-IN 5 | Others |
PD-1/PD-L1-IN 5 is an inhibitor of PD-1/PD-L1 protein/protein interaction (IC50 of ≤100 nM). | |||
T4696 | BMS202 hydrochloride (1675203-84-5(free base)) | PD-1/PD-L1 inhibitor 2 hydrochloride | PD-1/PD-L1 |
BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L... | |||
T3146 | BMS-202 | PD1-PDL1 inhibitor 2,PD-1/PD-L1 inhibitor 2 | Apoptosis , PD-1/PD-L1 |
BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction. | |||
T26859 | BMS-8 | PD-1/PD-L1 | |
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers. | |||
TP1463 | PD-1/PD-L1-IN 3 TFA (1629654-95-0 free base) | PD-1/PD-L1-IN 3 TFA | |
PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM. | |||
T72670 | PD-1/PD-L1-IN-13 | ||
PD-1/PD-L1-IN-13 is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM for PD-1/PD- L1 interaction.PD-1/PD-L1-IN-13 promotes CD8+ T-cell activation and delays tumour growth in a Hepa1-6 homozyg... | |||
T62501 | PD-1/PD-L1-IN-17 | ||
PD-1/PD-L1-IN-17 (Compound P20) is a potent PD-1/PD-L1 inhibitor (IC50: 26.8 nM). PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of PD-1/PD-L1 interactions. -17 has potential for cancer d... | |||
T72675 | PD-1/PD-L1-IN-23 | ||
PD-1/PD-L1-IN-23 is a potent, orally active ester prodrug of L7, a benzooxadiazole derivative, and functions as an inhibitor of PD-1/PD-L1. It has been biologically evaluated for its inhibitory effects on PD-L1, demonstr... | |||
T63614 | PD-1/PD-L1-IN-15 | ||
PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy. | |||
T79643 | PD-1/PD-L1-IN-33 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM. By doing so, it enhances T-cell proliferation, activation, and infiltration with... | |||
T72691 | PD-1/PD-L1-IN-28 | ||
PD-1/PD-L1-IN-28, an inhibitor of the PD-1/PD-L1 signaling pathway (IC 50 = 0.744 µM), demonstrates promising research potential in tumor immunity. This immune checkpoint inhibitor effectively blocks the interaction with... | |||
T63607 | PD-1/PD-L1-IN-22 | ||
PD-1/PD-L1-IN-22 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interactions that blocks PD-1/PD-L1 interactions (IC50: 0.732 μM). PD-1/PD-L1-IN-22 can be used to study cancer, infectious diseases and autoim... | |||
T61968 | PD-1/PD-L1-IN 6 | ||
PD-1/PD-L1-IN 6 (compound A13) is a potent inhibitor of PD-1/PD-L1 interaction (IC 50 = 132.8 nM). PD-1/PD-L1-IN 6 shows outstanding immunoregulatory activity. In a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, PD-1... | |||
T63329 | PD-1/PD-L1-IN-25 | ||
PD-1/PD-L1-IN-25 is an inhibitor of PD-1/PD-L1 interaction (IC50: 16.17 nM) that effectively activates anti-tumor immunity of T cells in PBMCs. PD-1/PD-L1-IN-25 can be used to study cancer. | |||
T79205 | PD-1/PD-L1-IN-34 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (K D = 0.1554 μM), resulting in the activation of the immune... | |||
T72668 | PD-1/PD-L1-IN-26 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-26 (Compound II-14) is a potent PD-1/PD-L1 inhibitor, demonstrating an IC50 of 0.0380 μM. It enhances the immune microenvironment by facilitating CD4+ T cell infiltration into tumor tissues, indicating pote... | |||
T72680 | PD-1/PD-L1-IN-27 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-27 is a potent inhibitor of PD-1/PD-L1, exhibiting an IC50 of 134 nM and demonstrating antitumor effects with minimal T cell cytotoxicity. It activates CD8+ T cells and mitigates T cell exhaustion [1]. | |||
T79314 | PD-L1-IN-3 | PD-1/PD-L1 | |
PD-L1-IN-3 (Compound 4a) functions as an inhibitor targeting the PD-1/PD-L1 axis, with an IC50 value of 4.97nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1/PD-L1... | |||
T8655 | SR-717 | STING | |
SR-717 is a cGAMP analog, a non-nucleoside STING agonist that induces a "closed" activation conformation of STING. SR-717 has antitumor activity and promotes activation of immune cells and cross-presentation of antigens. | |||
T61929 | PD-1/PD-L1-IN-14 | ||
PD-1/PD-L1-IN-14 (compound 17) is an inhibitor of PD-1/PD-L1 interaction (IC50=27.8 nM). By inhibiting the interaction of PD-1/PD-L1, PD-1/PD-L1-IN-14 promotes dimerization, endocytosis and degradation of PD-L1. | |||
T64086 | PD-1/PD-L1-IN-20 | ||
PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks the PD-1/PD-L1 interaction (IC50: 5.29 nM). PD-1/PD-L1-IN-20 can be used to study cancer, infectious disea... | |||
T72721 | PD-1/PD-L1-IN-29 | ||
PD-1/PD-L1-IN-29 (S4-1) is a potent inhibitor of the PD-1/PD-L1 interaction, with an IC50 value of 6.1 nM. It effectively binds to PD-L1, inhibiting the PD-1/PD-L1 interaction, promotes PD-L1 dimerization and its interna... | |||
T72724 | PD-1/PD-L1-IN-30 | ||
PD-1/PD-L1-IN-30 is a PD-1/PD-L1 binding inhibitor, with an IC 50 value of 0.018 μM. PD-1/PD-L1-IN-30 can be used for research of cancers and other related diseases . | |||
T62193 | PD-1/PD-L1-IN 5 | ||
PD-1/PD-L1-IN 5 is a potent PD-1/PD-L1 protein/protein interaction inhibitor (IC50 ≤ 100 nM). | |||
T63948 | PD-1/PD-L1-IN-16 | ||
PD-1/PD-L1-IN-16 is a potent inhibitor of PD-1/PD-L1 (IC50: 53.2 nM) and has shown research potential for tumour immunotherapy. | |||
T79576 | PD-1/PD-L1-IN-32 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM. It effectively suppresses tumor growth in the hPD-L1 MC38 humanized mouse model... | |||
T78755 | PD-1/PD-L1-IN-31 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood mononuclear cells (PBMCs), resulting in the inhibition of tumor cells... | |||
T61574 | PD-L1-IN-1 | ||
PD-L1-IN-1, a powerful PD-L1 inhibitor, demonstrated an IC50 of 115 nM. By forming a robust bond with the PD-L1 protein, PD-L1-IN-1 effectively suppressed tumor growth by enhancing the antitumor immune activity of periph... | |||
T78053 | PD-L1-IN-2 | PD-1/PD-L1 | |
PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity. In vivo studies indicate that it suppresses PD-L1 expression and amplifies tumor-infiltrating T-cell... | |||
T83724 | TPP-1 hydrochloride | Targeting PD-L1 Peptide | |
TPP-1, a peptide inhibitor, targets the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1), binding specifically to PD-L1 with a dissociation constant (Kd) of 94.67 nM. At a concentration o... | |||
T76080 | Human PD-L1 inhibitor V | PD-1/PD-L1 | |
Human PD-L1 Inhibitor V is a peptide that binds to the human PD-1 protein with an affinity characterized by a dissociation constant (Kd) of 3.32 μM, effectively inhibiting the hPD-1/hPD-L1 interaction [1]. | |||
T79739 | CYP51/PD-L1-IN-2 | ||
CYP51/PD-L1-IN-2 (compound L20), a quinazoline with antifungal properties, is a potent dual inhibitor targeting both CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM). The compound promotes early apoptosis in the fungal ... | |||
T73642 | PD-1/PD-L1-IN 3 TFA | ||
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, serves as a potent and selective inhibitor of PD-1/PD-L1 interaction. This compound disrupts PD-L1's binding with PD-1 and CD80 by directly binding to PD-L1, exhibiting IC50 va... | |||
T78902 | CYP51/PD-L1-IN-4 | ||
CYP51/PD-L1-IN-4 (compound 14a-2) is a potent dual-target inhibitor of CYP51/PD-L1, displaying IC50 values of 0.17 and 0.021 μM, respectively. This compound demonstrates significant antifungal efficacy and combats drug-r... | |||
T79740 | CYP51/PD-L1-IN-3 | ||
CYP51/PD-L1-IN-3 (compound L21), a quinazoline with antifungal properties, serves as a dual inhibitor targeting CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM). This compound promotes early fungal apoptosis within the ... | |||
T79738 | CYP51/PD-L1-IN-1 | ||
CYP51/PD-L1-IN-1 (compound L11), a quinazoline with antifungal properties, simultaneously inhibits CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM). This compound prompts early apoptosis in the fungal cell cycle, marked... | |||
T80209 | Human membrane-bound PD-L1 polypeptide | PD-1/PD-L1 | |
Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1]. | |||
T76080L | Human PD-L1 inhibitor V TFA | ||
Human PD-L1 Inhibitor V TFA, a peptide that binds to the human PD-1 protein, exhibits a dissociation constant (Kd) of 3.32 μM and effectively inhibits the hPD-1/hPD-L1 interaction [1]. | |||
T78270 | Anti-Mouse PD-L1 Antibody (10F.9G2) | PD-1/PD-L1 | |
Anti-Mouse PD-L1 Antibody is a rat-derived IgG2b monoclonal antibody that inhibits mouse PD-L1. |
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T6S0071 | Fraxinellone | HIF/HIF Prolyl-Hydroxylase , STAT , PD-1/PD-L1 | |
1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhibited a variety of insecticidal activities including feeding... | |||
T2763 | Panaxadiol | 20(R)-Panaxadiol | Others , HIF/HIF Prolyl-Hydroxylase |
Panaxadiol (20(R)-Panaxadiol) is a novel antitumor agent extracted from the Chinese medical herb Panax ginseng. | |||
TN1051 | 1-Caffeoylquinic acid | NF-κB | |
1-Caffeoylquinic acid is an important intermediate in lignin biosynthesis. 1-Caffeoylquinic acid has anti-influenza, and antioxidant activities, it also slows the release of glucose into the bloodstream after a meal. |
カタログ番号 | 製品名 | Species | Expression System |
---|---|---|---|
TMPY-04343 | PD-L1 Protein, Human, Recombinant (His) | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.8 kDa and the accession number is Q9NZQ7-1. | |||
TMPY-05208 | PD-L1 Protein, Human, Recombinant | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 25.2 kDa and the accession number is Q9NZQ7-1. | |||
TMPY-04949 | PD-L1 Protein, Human, Recombinant (His), Biotinylated | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.8 kDa and the accession number is Q9NZQ7-1. | |||
TMPY-00237 | PD-L1 Protein, Canine, Recombinant (hFc) | Canine | HEK293 Cells |
PD-L1 Protein, Canine, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 51.5 kDa and the accession number is A0A8C0MRV9. | |||
TMPY-04345 | PD-L1 Protein, Rat, Recombinant (His) | Rat | HEK293 Cells |
PD-L1 Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.5 kDa and the accession number is A6I0W4. | |||
TMPY-01155 | PD-L1 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells |
PD-L1 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.3 kDa and the accession number is Q3U472. | |||
TMPY-05238 | PD-L1 Protein, Human, Recombinant (hFc), Biotinylated | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 52 kDa and the accession number is Q9NZQ7-1. | |||
TMPY-03670 | PD-L1 Protein, Cynomolgus/Rhesus, Recombinant (His) | Cynomolgus,Rhesus | HEK293 Cells |
PD-L1 Protein, Cynomolgus/Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 52 kDa and the accession number is XP_015292694.1&XP_014973151.1. | |||
TMPY-00676 | PD-L1 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 52 kDa and the accession number is Q9NZQ7-1. | |||
TMPY-04648 | PD-L1 Protein, Human, Recombinant (mFc) | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 51.7 kDa and the accession number is Q9NZQ7-1. | |||
TMPY-06276 | PD-L1 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 28.48 kDa and the accession number is Q9NZQ7-1. | |||
TMPJ-00638 | PD-L1 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells |
PD-L1 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 32-40 KDa and the accession number is G7PSE7. | |||
TMPJ-00183 | PD-L1 Protein, Human, Recombinant (Flag) | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (Flag) is expressed in HEK293 mammalian cells with C-Flag tag. The predicted molecular weight is 35-40 KDa and the accession number is Q9NZQ7. | |||
TMPJ-00637 | PD-L1 Protein, Cynomolgus, Recombinant (hFc) | Cynomolgus | HEK293 Cells |
PD-L1 Protein, Cynomolgus, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-Fc tag. The predicted molecular weight is 73 KDa and the accession number is G7PSE7. | |||
TMPK-00662 | PD-L1 Protein (Primary Amine Labeling), Cynomolgus/Rhesus macaque, Recombinant (His), Biotinylated | Cynomolgus,Rhesus | HEK293 Cells |
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 has been identified as the ligand for the immunoinhibitory receptor progr... | |||
TMPK-00182 | PD-L1 Protein, Human, Recombinant (aa 19-238, His & Avi), Biotinylated | Human | HEK293 Cells |
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 has been identified as the ligand for the immunoinhibitory receptor progr... | |||
TMPJ-00182 | PD-L1 Protein, Human, Recombinant (hFc & Avi), Biotinylated | Human | HEK293 Cells |
PD-L1 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-Fc-Avi tag. The predicted molecular weight is 70-95 KDa and the accession number is Q9NZQ7. | |||
TMPY-04344 | PD-L1 Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells |
PD-L1 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 51.6 kDa and the accession number is Q3U472. | |||
TMPY-03718 | PD-L1 Protein, Rat, Recombinant (hFc) | Rat | HEK293 Cells |
PD-L1 Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 51.8 kDa and the accession number is A6I0W4. | |||
TMPY-06181 | PD-L1 Protein, Canine, Recombinant (hFc), Biotinylated | Canine | HEK293 Cells |
PD-L1 Protein, Canine, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 51.5 kDa and the accession number is A0A8C0MRV9. | |||
TMPY-03801 | PD-L1 Protein, Cynomolgus/Rhesus, Recombinant (hFc) | Cynomolgus,Rhesus | HEK293 Cells |
PD-L1 Protein, Cynomolgus/Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with Fc tag. The predicted molecular weight is 52.3 kDa and the accession number is XP_015292694.1. | |||
TMPY-05132 | PD-L1 Protein, Mouse, Recombinant (His), Biotinylated | Mouse | HEK293 Cells |
PD-L1 Protein, Mouse, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.2 kDa and the accession number is Q3U472. | |||
TMPY-05505 | PD-L1 Protein, Cynomolgus/Rhesus, Recombinant (His), Biotinylated | Cynomolgus,Rhesus | HEK293 Cells |
PD-L1 Protein, Cynomolgus/Rhesus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.7 kDa and the accession number is XP_015292694.1. | |||
TMPY-05647 | PD-L1 Protein, Mouse, Recombinant (hFc & Avi), Biotinylated | Mouse | HEK293 Cells |
PD-L1 Protein, Mouse, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 53.3 kDa and the accession number is Q3U472. | |||
TMPY-06977 | PD-L1 Protein, Mouse, Recombinant (His & Avi), Biotinylated | Mouse | HEK293 Cells |
PD-L1 Protein, Mouse, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 28.02 kDa and the accession number is NP_068693.1. | |||
TMPK-01290 | PD-L2 Protein, Cynomolgus, Recombinant (aa 20-220, His) | Cynomolgus | HEK293 Cells |
PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine pr... | |||
TMPK-00166 | PD-L2 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells |
PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine pr... | |||
TMPJ-00181 | PD-1 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells |
Programmed cell death protein 1(PDCD1) is a single-pass type I membrane protein and contains 1 Ig-like V-type domain. PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 inhibits the T-cell pr... |
カタログ番号 | 製品名 | ||
---|---|---|---|
L2191 | Anti-Breast Cancer Compound Library | 1939 compounds | |
A unique collection of 1939 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study; |